1. Show article details.

    Peregrine Pharmaceuticals to Present at Two Upcoming Cancer Immunotherapy Conferences

    GlobeNewswire – 8:05 AM ET 01/20/2016

    Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that members of the company’s scientific team will deliver podium presentations focused on the role of combination immunotherapies in the treatment of cancer at two upcoming immunotherapy conferences.

  2. Show article details.

    Peregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program in Lung, Breast and Other Cancers

    GlobeNewswire – 8:05 AM ET 01/11/2016

    -- Phase II Study in NSCLC in Collaboration with AstraZeneca Evaluating Bavituximab Plus Durvalumab to Expand Lung Cancer Program in Q1 2016 -- -- Phase II/III Study in HER2-Negative Metastatic Breast Cancer is Now Underway with a Second Phase II Study in Early Stage Triple Negative Breast Cancer to Begin in Q1 2016 -- -- Additional Studies to Broaden Evaluation of Bavituximab Immunotherapy and...

  3. Show article details.

    Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With Bavituximab

    GlobeNewswire – 8:05 AM ET 01/06/2016

    Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced a new research collaboration with the National Comprehensive Cancer Network® to expand the company’s ongoing clinical research and development of bavituximab for the treatment of a range of tumors.

  4. Show article details.

    The Life Sciences Report Announces 19 Companies for the 2016 Small-Cap Biotech Watchlist

    Market Wire – 9:00 AM ET 12/22/2015

    12/22/15 -- In advance of the Biotech Showcase 2016, The Life Sciences Report has once again solicited top analysts to provide the names of innovative biotech companies that investors should keep an eye on in the upcoming year.

  5. Show article details.

    Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2016 and Recent Developments

    GlobeNewswire – 4:05 PM ET 12/10/2015

      --Peregrine and AstraZeneca Expand Immuno-Oncology Collaboration and Plan Phase II NSCLC Trial-- --Phase III SUNRISE Clinical Trial Expected to Complete Enrollment in Coming Weeks While New Clinical Trials Are Being Initiated-- --Peregrine Closes $20 Million Financing to Support Late-Stage Clinical Trials-- --Biomanufacturing Business, Avid Bioservices, Posts Strong Quarter With a 52% Increas...

  6. Show article details.

    Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock

    GlobeNewswire – 4:05 PM ET 12/07/2015

    Peregrine Pharmaceuticals, Inc. (PPHM) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock. The quarterly dividend on the Series E Preferred Stock is payable on January 4, 2016 to holders of record at the close of business on December 18, 2015.

  7. Show article details.

    Peregrine to Report Financial Results for Second Quarter of Fiscal Year 2016 After Market Close on December 10, 2015

    GlobeNewswire – 4:05 PM ET 12/03/2015

    Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it will report financial results for the second quarter of fiscal year 2016 ended October 31, 2015 on December 10, 2015 after market and will host a conference call and webcast at 1:30 PM Pacific Time.

  8. Show article details.

    Peregrine Pharmaceuticals to Participate in Two Upcoming Life Science Investor Conferences

    GlobeNewswire – 8:05 AM ET 11/23/2015

    Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that the company will participate in two upcoming life science investor conferences being held in New York during the month of December.

  9. Show article details.

    New Preclinical Data Presented at SITC Annual Meeting Highlight Bavituximab’s Enhanced Anti-Tumor Activity When Combined With Checkpoint Inhibitors in Breast Cancer and Melanoma

    GlobeNewswire – 8:05 AM ET 11/09/2015

    - Bavituximab in Combination with Anti-PD-1 in Breast Cancer Studies Showed a Statistically Significant Improvement in Overall Survival as Compared to Subjects Receiving Anti-PD-1 Therapy Alone - - New Custom-Designed Immuno-Profiling Clinical Test Provides Further Evidence of Bavituxmab’s Immune Modulating Mechanism of Action in the Tumor Microenvironment - TUSTIN, Calif., Nov. 09, 2015 -- Per...

  10. Show article details.

    AstraZeneca and Peregrine Pharmaceuticals Expand Ongoing Immuno-Oncology Collaboration to Include Phase II Lung Cancer Combination Clinical Trial

    GlobeNewswire – 8:05 AM ET 10/15/2015

    Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it has expanded its ongoing cancer immunotherapy clinical collaboration with AstraZeneca to include a second, later-stage trial.

  11. Show article details.

    Peregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2016 and Recent Developments

    GlobeNewswire – 4:05 PM ET 09/09/2015

    --Peregrine and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial-- --Phase III SUNRISE Clinical Trial on Track to Complete Patient Enrollment by Calendar Year-End 2015-- --Avid Bioservices Reports $9.4 Million in First Quarter Revenue-- TUSTIN, Calif., Sept. 09, 2015 -- Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company focused on developing therapeutics to sti...

  12. Show article details.

    Peregrine Pharmaceuticals Declares Quarterly Dividend On Its Series E Convertible Preferred Stock

    GlobeNewswire – 4:05 PM ET 09/08/2015

    Peregrine Pharmaceuticals, Inc. (PPHM) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock. The quarterly dividend on the Series E Preferred Stock is payable on October 1, 2015 to holders of record at the close of business on September 18, 2015.

  13. Show article details.

    New Translational Data Highlights Bavituximab’s Ability to Induce Signs of Immune Activation in Lung Cancer Tumor Samples With Negative PD-L1 Expression

    GlobeNewswire – 8:05 AM ET 09/08/2015

    Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced positive new data from a translational study of bavituximab, the company’s investigational phosphatidylserine-signaling pathway inhibitor.

  14. Show article details.

    Peregrine to Report Financial Results for First Quarter of Fiscal Year 2016 After Market Close on September 9, 2015

    GlobeNewswire – 4:05 PM ET 09/03/2015

    Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it will report financial results for the first quarter of fiscal year 2016 ended July 31, 2015 on September 9, 2015 after market and will host a conference call and webcast at 1:30 PM Pacific Daylight Time.

  15. Show article details.

    Peregrine Pharmaceuticals Presents Data at Annual Immunotherapy and Vaccine Summit (ImVacS) Supporting Ability of Bavituximab to Mediate Anti-Tumor T Cell Responses Across Multiple Tumor Types

    GlobeNewswire – 9:00 AM ET 08/26/2015

    - Increasing Activated T Cells in Tumors Demonstrates Potential Complement to anti-PD-1 and anti-PD-L1 Checkpoint Inhibitors - - Clinical and Preclinical Studies Demonstrate Estimated Survival Curves that Plateau - Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced the presentatio...

  16. Show article details.

    AstraZeneca and Peregrine Pharmaceuticals to Collaborate on Immuno-Oncology Combination Clinical Trial

    GlobeNewswire – 2:05 AM ET 08/24/2015

    AstraZeneca (AZN) and Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that they have entered into a cancer immunotherapy clinical trial collaboration.

Page:

Today's and Upcoming Events

  • Mar
    10

    PPHM to announce Q3 earnings After Market (Unconfirmed)

Past Events (last 90 days)

No events in the past 90 days

Data provided by Wall Street Horizon, Inc. © 2016

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.